ReproCELL Incorporated

4978・Growth Market・Chemicals

Official website

ReproCELL Incorporated

4978・Growth Market・Chemicals

Official website

ReproCELL Incorporated4978

Reference Indicators

Market Cap

121¥100M

P/E (Forecast)

—

P/B

1.4x

Dividend Yield (Forecast)

0.00%

ROE

-7.0%

EV/EBITDA

—

Financial Summary

Unit: ¥M

Item	2022Mar 2022	2023Mar 2023	2024Mar 2024	2025Mar 2025	2026Mar 2026
Net Sales	2,234	2,953	2,426	2,978	2,233
Cost of Sales	1,431	1,812	1,305	1,329	1,218
Gross Profit	803	1,141	1,120	1,649	1,015
SG&A Expenses	1,450	1,497	1,530	1,779	1,875
Operating Income	-647	-356	-409	-130	-860
Non-operating Income	205	242	458	202	308
Non-operating Expenses	66	5	9	26	29
Ordinary Income	-507	-119	40	45	-581
Extraordinary Losses	66	183	69	—	6
Pre-tax Income	-573	-303	-28	45	-587
Income Taxes	1	1	2	-58	4
Net Income	-575	-305	-31	103	-591
EBITDA	-587	-307	-372	-79	-785
Gross Margin	36.0%	38.6%	46.2%	55.4%	45.5%
Operating Margin	-29.0%	-12.1%	-16.9%	-4.4%	-38.5%
ROA	-7.1%	-3.7%	-0.3%	1.1%	-6.1%
ROE	-7.9%	-4.0%	-0.4%	1.2%	-7.0%

Segment Performance

Unit: ¥M

2026

Segment	Net Sales	Operating Income	Operating Margin
研究支援事業	1,952	0	0.0%
メディカル事業	281	0	0.0%